{"id":"placebo-matching-dostarlimab","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Nausea"},{"rate":"15-20","effect":"Anemia"},{"rate":"5-10","effect":"Immune-mediated colitis"},{"rate":"2-5","effect":"Pneumonitis"},{"rate":"5-10","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL4298124","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dostarlimab binds to programmed death receptor 1 (PD-1) on the surface of T lymphocytes, preventing engagement with PD-L1 and PD-L2 expressed on tumor and antigen-presenting cells. This blockade restores T cell activation, proliferation, and effector functions, enabling the immune system to mount an anti-tumor response. The drug is administered intravenously and has demonstrated clinical activity across multiple cancer types, particularly those with mismatch repair deficiency or high microsatellite instability.","oneSentence":"Dostarlimab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:51.674Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer"},{"name":"Recurrent or advanced endometrial cancer"}]},"trialDetails":[{"nctId":"NCT03981796","phase":"PHASE3","title":"A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2019-07-18","conditions":"Neoplasms","enrollment":785}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching dostarlimab","genericName":"Placebo matching dostarlimab","companyName":"Tesaro, Inc.","companyId":"tesaro-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dostarlimab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer cells. Used for Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer, Recurrent or advanced endometrial cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}